LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lifevantage Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 27, 2026
$5.98−0.02 (-0.33%)
Close on Oct 19, 2026
- Market cap
- $74.97M
- P/E (TTM)
- 15.0
- Dividend yield
- 3.09%
Lifevantage Corp balance sheet
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 77.6%
- Operating margin
- 3.3%
- Net margin
- 2.8%
- Return on equity, FY2026
- 14.9%
Financial strength
- Current ratio
- 1.89
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 73.8%
Valuation
- P/E ratio
- 15.0
- Price to sales
- 0.41
- Price to book
- 2.23
- Dividend yield
- 3.09%